CME Outfitters, LLC, announces an upcoming live and interactive CE activity titled "Making Real-World Treatment Decisions about Schizophrenia: The CATIE Trial." Offered as a live satellite broadcast, webcast, and telephone audioconference premiering Wednesday, August 24, 2005, from 12:00 p.m.-1:00 p.m. ET, the activity will focus on providing current and clinically relevant data about the efficacy and cost-effectiveness of a variety of different antipsychotics used to treat schizophrenia.
Rockville, MD July 26, 2005 -- CME Outfitters, LLC, nationally accredited provider of multidisciplinary medical education programming and related healthcare communications services, is pleased to announce an upcoming live and interactive CE activity titled "Making Real-World Treatment Decisions about Schizophrenia: The CATIE Trial."
Offered as a live satellite broadcast, webcast, and telephone audioconference premiering Wednesday, August 24, 2005, from 12:00 p.m.-1:00 p.m. ET, the activity will focus on providing current and clinically relevant data about the efficacy and cost-effectiveness of a variety of different antipsychotics used to treat schizophrenia. The recorded satellite broadcast will re-air from 3:00 p.m.-4:00 p.m. ET. This CE activity will be available as an archived webcast, podcast, and telephone audioconference shortly after the live broadcast, and available as a videotape or multimedia CD-ROM in September.
Participation in this activity is free, as is obtaining a CE certificate; however, registration is required. Three forms of registration are accepted:
Fax: View the activity details page at http://www.psychCME.net/cmea.aspID=120, print and complete the activity details form, and fax to 240.243.1033
Online: Visit the psychCME TV page at http://www.psychCME.net
Phone: Call 877.CME.PROS (877.263.7767)
Statement of Need:
Schizophrenia is a severe, debilitating mental illness, complicated by the challenge of achieving treatment efficacy and compliance. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial was designed so that researchers could gain important information about long-term outcomes and cost-effectiveness of a number of medications already used to treat schizophrenia. CATIE was launched in 2000, and is a double-blind, randomized comparison of atypical antipsychotics with each other and with a conventional antipsychotic, perphenazine. It is considered a "practical" clinical trial because participants were recruited from the community at large and because the interventions tested are already in widespread use. Patients were followed for 18 months; if at any time during the trial an assigned medication was ineffective or not well-tolerated, patients were re-randomized to other treatment pathways. Data collection in the study was completed in December 2004 and data analyses are being carried out through 2005. The initial publication is expected in the summer of 2005. The final data are designed to answer three questions:
- Are newer drugs more effective than the older drugs
- How do newer drugs compare to each other
- Which of the medications are the most effective and safe
In this landmark psychCME TV activity, CATIE researchers will share their results with clinicians who are interested in making informed, real-world decisions about treating patients with schizophrenia.
psychCME Chair and Moderator:
Prakash S. Masand, MD
Consulting Professor of Psychiatry
Duke University Medical Center
Durham, NC
Faculty:
Jeffrey A. Lieberman, MD
Chairman, Department of Psychiatry
College of Physicians and Surgeons, Columbia University
Director, New York State Psychiatric Institute
Director, Lieber Center for Schizophrenia Research
Psychiatrist-in-Chief at New York Presbyterian Hospital & Columbia University Medical Center
New York, NY
Diana O. Perkins, MD, MPH
Associate Professor of Psychiatry
Director of the Schizophrenia Treatment and Evaluation Program
University of North Carolina at Chapel Hill
Chapel Hill, NC
Learning Objectives:
At the end of this CE activity, participants should be able to:
- Assess the strengths of the current evidence supporting the efficacy and cost-effectiveness of various atypical antipsychotics.
- Utilize clinical judgement to select the best targeted treatment for individual patients with schizophrenia.
- Recognize the clinical merit of trials that include participants who reflect a wide range of disease states and phenomenology.
Target Audience:
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals with an interest in mental health.
Commercial Support:
CME Outfitters, LLC, gratefully acknowledges an educational grant from Pfizer Inc. in support of this CE activity.
Credit Information:
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CME Outfitters, LLC, designates this educational activity for a maximum of 1.0 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.
CNE Credit (Nurses):
This Educational Activity is presented by CME Outfitters, LLC, which has been approved as a provider of continuing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. It has been assigned code 5UYSJZ-PRV-0460. 1.2 contact hours (Pharmacology)
CEP Credit (Psychologists):
CME Outfitters, LLC, is approved by the American Psychological Association to offer continuing education for psychologists. CME Outfitters, LLC, maintains responsibility for the program. 1.0 CE credits
NASW Credit (Social Workers):
This program was approved by the National Association of Social Workers (provider #886407722) for 1 continuing education contact hour.
CCMC Credit (Certified Case Managers):
This program has been approved for 1 hour by the Commission for Case Manager Certification (CCMC).
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Program Number:
376-999-05-015-L01 (live presentation)
376-999-05-015-H01 (recorded programs)
To receive credit, participants must review all activity materials in their entirety, score 70% or above on a post-test, and fully complete and return both the credit request form and activity evaluation. A certificate or statement of credit will be mailed within 4-6 weeks to all who successfully complete these requirements.
About CME Outfitters:
CME Outfitters is a full service healthcare communications agency providing continuing education content development, production, marketing, accreditation, and project management services to the healthcare industry. Among its many collaborative ventures, CME Outfitters enjoys an exclusive role in producing, certifying, and supporting the popular psychCME series of educational activities originally developed at Duke University Medical Center. For more information on CME Outfitters, including a complete calendar of its free award-winning educational activities, please visit http://www.cmeoutfitters.com or call 877.CME.PROS (877.263.7767).
To view all of CME Outfitters' recent press releases, visit http://www.cmeoutfitters.com and click on "CME Outfitters in the News" or visit http://www.prweb.com and search for "CME Outfitters."
CME Outfitters' weekly e-newsletter, psychCME EXTRA, is a convenient way to stay informed of all CME Outfitters news and information. To subscribe, visit http://www.cmeoutfitters.com and click on "Register for Updates."
Contact: Christopher Perez
CME Outfitters, LLC
240.243.1303 direct
240.243.1033 fax
CME Outfitters Announces Live psychCME TV Activity Making RealWorld Treatment Decisions about Schizophrenia The CATIE Trial Premieres Wednesday August 24 2005




